PharmaCom BioVet, Inc. Introduces Novel Cancer Treatments in Partnership With IsoTherapeutics Group
October 15 2008 - 8:41AM
Marketwired
PharmaCom BioVet, Inc. (PINKSHEETS: PHMB) is pleased to announce
they have entered into a collaborative agreement with
IsoTherapeutics Group (ITG) to co-develop and introduce novel
therapeutic treatments for companion animals.
With a special interest in radiopharmaceuticals for oncology,
ITG focuses on the development of technologies aiding in the
diagnosis and treatment of debilitating diseases such as
cancer.
"PharmaCom BioVet's relationship with IsoTherapeutics Group will
enable significant development in the research of a variety of
therapeutic treatments geared towards lymphoma and other forms of
companion animal cancers," said Gary Berthold, Founder,
President/CEO of PharmaCom BioVet, Inc. "Through these efforts,
PharmaCom BioVet will be poised to introduce novel treatment
procedures throughout our cancer centers and the veterinary
community."
"ITG is developing novel technologies for the therapeutic
treatment of cancers," said R. Keith Frank, Ph.D., Co-Founder and
President/CEO of IsoTherapeutics Group, LLC. "Through our
relationship with PharmaCom BioVet we are excited that we will be
able to introduce these new treatments into the veterinary
marketplace."
PharmaCom BioVet, Inc. seeks to further the opportunities
available to people who have encountered cancer in their companion
animals and to offer their animals a better quality of life and
longevity. In response to demand and the current lack of adequate
cancer treatment options and facilities for animal lovers whose
pets are suffering from cancer, PharmaCom BioVet intends to open a
network of companion animal cancer care centers throughout North
America.
About PharmaCom BioVet, Inc.:
PharmaCom BioVet, Inc. is dedicated to advancing the Veterinary
care industry for companion animals by establishing
state-of-the-art treatment centers for lymphoma and other forms of
cancer throughout the country. The purpose of these centers is to
help prolong the quality of life for companion animals with cancer
and pursue the potential for complete cure. These centers will also
operate under the philosophy of providing a compassionate care
environment for both companion animal patients and their owners.
For more information, please visit our website
www.PharmaComBioVet.com.
About IsoTherapeutics Group, LLC:
The mission of IsoTherapeutics Group, LLC is to develop novel
diagnostic and therapeutic agents for the treatment of severe
diseases. ITG develops both proprietary technologies as well as
partners with other companies to help develop pharmaceuticals. Of
special interest are radiopharmaceuticals for oncology. In house
expertise includes synthetic organic chemistry, chelation
chemistry, radiochemistry, diagnostic and therapeutic isotopes,
conjugation chemistry, pharmacokinetics, and small animal research
models. For more information, please visit our website
www.isotherapeutics.com.
DISCLOSURE:
"Safe Harbor" statement under the Private Securities Litigation
Reform Act of 1995: This press release contains forward-looking
statements that are subject to risk and uncertainties, including,
but not limited to, the impact of competitive products, product
demand, market acceptance risks, fluctuations in operating results,
political risk and other risks detailed from time to time in
PharmaCom BioVet, Inc.'s filings with the Securities and Exchange
Commission. These risks could cause PharmaCom BioVet, Inc.'s actual
results to differ materially from those expressed in any
forward-looking statements made by, or on behalf of, PharmaCom
BioVet, Inc.
Contact: Market Ideas, Inc. 877-295-3981 ext. 2
info@marketideasinc.com
PharmaCom BioVet (CE) (USOTC:PHMB)
Historical Stock Chart
From Sep 2024 to Oct 2024
PharmaCom BioVet (CE) (USOTC:PHMB)
Historical Stock Chart
From Oct 2023 to Oct 2024